Comments on the Food and Drug Administration (FDA) Cardiac and Renal Drugs Advisory Committee Recommended Guidelines for the Conduct of Antianginal Drug Trials

Author(s):  
Udho Thadani
2021 ◽  
Vol 10 (3) ◽  
pp. 122-122
Author(s):  
Charles L Bennett

Biosimilars are biological drug products that are highly similar to reference products in analytic features, pharmacokinetics and pharmacodynamics, immunogenicity, safety and efficacy. Biosimilar epoetin received US Food and Drug Administration (FDA) approval in 2018 [1]. The manufacturer received an FDA non-approval letter in 2017, despite receiving a favourable review by the FDA’s Oncologic Drugs Advisory Committee (ODAC) and an FDA non-approval letter in 2015 for an earlier formulation.


JAMA ◽  
2006 ◽  
Vol 295 (16) ◽  
pp. 1921 ◽  
Author(s):  
Peter Lurie ◽  
Cristina M. Almeida ◽  
Nicholas Stine ◽  
Alexander R. Stine ◽  
Sidney M. Wolfe

Circulation ◽  
2014 ◽  
Vol 130 (15) ◽  
pp. 1287-1294 ◽  
Author(s):  
Nevin C. Baker ◽  
Michael J. Lipinski ◽  
Thibault Lhermusier ◽  
Ron Waksman

Sign in / Sign up

Export Citation Format

Share Document